eligibility_summary
Adults 18-70 with unresectable/metastatic select soft-tissue sarcomas, no prior systemic therapy for advanced disease (or relapse >6 mo post adjuvant), measurable disease (RECIST 1.1), ECOG 0-1, life >=6 mo, adequate organ/pulmonary function, consent/contraception. Exclude recent anti-cancer therapy, immunosuppressants/modulators, disallowed histologies, high prior anthracycline dose, infections, autoimmune or active CNS disease, major CV issues/effusions, recent surgery/trial, transplant, or other risks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Phase II, first-line therapy for advanced soft tissue sarcoma. Interventions: MASCT-I (biologic, autologous cellular immunotherapy comprising dendritic cells and effector T cells) plus doxorubicin and ifosfamide vs doxorubicin/ifosfamide alone. Mechanisms: MASCT-I uses dendritic cells to present tumor antigens (MHC I/II) and activate tumor-specific T cells, infused effector T cells mediate cytotoxicity (perforin/granzyme, IFN-γ). Doxorubicin is an anthracycline topoisomerase II inhibitor that intercalates DNA and generates ROS, inducing DNA damage and immunogenic cell death. Ifosfamide is an oxazaphosphorine alkylating agent causing DNA crosslinks. Targets: dendritic cells, CD8+ T cells/TCR signaling, antigen-presentation pathways, and tumor cell DNA integrity. Synergy expected via chemotherapy-driven antigen release and immune priming.